Drug delivery systems for antihypertensive agents

Blood Pressure Monitoring

Volumn 2, Issue 1, 1997, Pages 53-60

  Elliott, William J ^a   Prisant, L Michael ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

COER 24; Covera HS; Drug delivery; Hypertension; Verapamil

Indexed keywords

ALGINIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DILTIAZEM; DIURETIC AGENT; FELODIPINE; GEOMATRIX; HYDROCHLOROTHIAZIDE PLUS PROPRANOLOL; METOPROLOL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; PROPRANOLOL; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG PELLET; DRUG SAFETY; HEART INFARCTION; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STROKE; SUDDEN DEATH; SUSTAINED RELEASE PREPARATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030972625     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Frishman WH, Rosenberg A, Katz B: Calcium antagonists in the management of systemic hypertension: the impact of sustained-release drug-delivery systems. Coronary Artery Dis 1994, 5:4-13.
2. Prisant LM, Bottini B, DiPiro JT, Carr AA: Novel drug-delivery systems for hypertension. Am J Med 1992, 93 (suppl 2A):45S-55S.
3. The Wall Street Journal. New York, NY, May 7, 1996, p B3.
4. Schoenberger JA, Wilson DJ: Once-daily treatment of essential hypertension with captopril. J Clin Hypertens 1986, 2:379-387.
5. Zannad F: Practical relevance of the 24-hour trough:peak ratio of antihypertensive drugs. J Hypertens 1995, 13 (suppl 2):S109-S112.
6. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990, 150:1881-1884.
7. Prisant LM, Carr AA, Bottini PB, Kaesemeyer WH: Nifedipine GITS (Gastrointestinal Therapeutic System) bezoar. Arch Intern Med 1991, 151:1868-1869.
8. Burris JF: The USA experience with the clonidine transdermal therapeutic system. Clin Auton Res 1993, 3:391-396.
9. Langley MS, Heel RC: Transdermal clonidine: a preliminary review of Its pharmacodynamic properties and therapeutic efficacy. Drugs 1988, 35:123-142.
10. Metz S, Klein C, Morton N: Rebound hypertension after discontinuation of transdermal clonidine therapy. Am J Med 1987, 82:17-19.
11. Groth H, Vetter H, Knuesel J, Vetter W: Allergic skin reactions to transdermal clonidine. Lancet 1983, ii:850-851.
12. Ito MK, O'Connor DT: Skin pretreatment and the use of transdermal clonidine. Am J Med 1991, 91 (suppl 1A):42S-49S.
13. Shaw JE: Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route. Am Heart J 1984, 108:217-223.
14. McAinsh J, Baber NS, Holmes BF, Young J, Ellis SH: Bioavailabililty of sustained release propranolol formulations. Biopharm Drug Dispos 1981, 2:39-48.
15. Nace GS, Wood AJJ: Pharmacokinetics of long acting propranolol: implications for therapeutic use. Clin Pharmacokinet 1987, 13:51-64.
16. Sandberg A, Ragnarsson G, Jonsson UE, Sjögren J: Design of a new multiple-unit controlled release formulation of metoprolol-metoprolol CR. Eur J Clin Pharmacol 1988, 33 (suppl):S3-S7.
17. Plosker GL, Clissold SP: Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Drugs 1992, 43:382-414.
18. Dimenäs E, Dahlöf C: Tolerability and well-being with metoprolol in a controlled release (CR/ZOK) formulation: a review article. J Clin Pharmacol 1990, 30 (suppl):S92-S97.
19. 2-adrenergic receptors. Hypertension 1994, 24:339-346.
20. Michelson EL: Calcium antagonists in cardiology: update on sustained-release drug delivery systems. Clin Cardiol 1991, 14:947-950.
21. McEwen J, Durnin C, McMurdo ET, Moreland TA: Sustained-release verapamil: multiple dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet. J Cardiovasc Pharmacol 1989, 13 (suppl 4):S57-S59.
22. Echizen H, Manz M, Eichelbaum M: Electrophysiologic effects of dextro-and levo-verapamil on sinus node and AV node function in humans. J Cardiovasc Pharmacol 1988, 12:543-546.
23. Karim A, Piergies A: Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both? Clin Pharmacol Ther 1995, 58:174-184.
24. Devane JG, Kelly JG: Effect of food on the bioavailability of a multiparticulate sustained release verapamil preparation. Adv Ther 1991, 8:42-46.
25. Carr AA, Bottini PB, Prisant LM, Fisher LD, Devane JG, O'Brien E, et al.: Once-daily verapamil in the treatment of mild-to moderate hypertension: a double-blind placebo-controlled dose-ranging study. J Clin Pharmacol 1991, 31:144-150.
26. Graney WF: Clinical experience with a once-daily, extended-release formulation of diltiazem in the treatment of hypertension. Am J Med 1992, 93 (suppl 2A):56S-64S.
27. Lewis BS: Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction. Am J Cardiol 1995, 75:46E-53E.
28. Zannad F: Clinical pharmacology of nisoldipine coat core. Am J Cardiol 1995, 75:41E-45E.
29. Hashiguchi M, Ogata H, Maeda A, Hirashima Y, Ishii S, Mori Y, et al.: No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil. J Clin Pharmacol 1996, 36:1022-1028.
30. Feig PU, Gibson L, MacCarthy EP, Pettis PP, Schwartz L, and the Adalat CC Cooperative Study Group: The efficacy and safety of once-daily nifedipine coat-core in the treatment of mild-to-moderate hypertension. Clin Ther 1993, 15:963-975.
31. Glasser SP, Ripa SR, Allenby KS, Schwartz LA, Commins BM, Jungerwirth S on behalf of the Nifedipine Study Group: The efficacy and safety of once-daily nifedipine administered without food: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate hypertension. Clin Ther 1995, 17:296-312.
32. Myers MG, Toal CB: Comparative efficacy of two long-acting formulations of nifedipine in the treatment of hypertension. The Switch Study Investigators. Can J Cardiol 1995, 11:913-917.
33. Todd PA, Faulds D: Felodipine: A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 1992, 44:251-277.
34. Webster J, Petrie JC, Jeffers TA, Roy CP, Crichton W, Witte K, et al.: Nicardipine sustained release in hypertension. Br J Clin Pharmacol 1991, 32:433-439.
35. Fagan TC, Tyler ED, Reitman MA, Kenley S, Weber MA: Sustained-release nicardipine in mild-to-moderate hypertension. Chest 1993, 104:427-433.
36. Brogden RN, McTavish D: Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 1995, 50:495-512.
37. Murdoch D, Brogden RN: Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs 1991, 41:737-779.
38. Krakoff LR: Effectiveness of nifedipine gastrointestinal therapeutic system for treatment of hypertension: results of the MATH trial. J Cardiovasc Pharmacol 1993, 21 (suppl 2):S14-S17.
39. White WB, Anders RJ, MacIntyre JM, Black HR, Sica DA and the Verapamil Study Group: Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Am J Cardiol 1995, 76:375-380.